Bayer AG adds a brand to its US OTC allergy remedy lineup as the Food and Drug Administration adds a first-in-class ingredient to the products it has approved for nonprescription sales with a partial OTC switch of azelastine hydrochloride nasal spray, 0.15%.
The FDA’s Center for Drug Evaluation and Research on 17 June announced approval of an application Bayer Healthcare LLC submitted...







